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Key Findings
It should be noted that the ordering of the 
key findings below is according to the order of 
appearance in the bulletin and is not intended 
to reflect the order of importance of the findings. 
It should also be noted that the figures presented 
for prevalence are for that specific combination 
only and do not provide information on individual 
substances unless specified. In this bulletin, 
polydrug use is defined as using any two or 
more substances, legal1, illegal or prescribed, in 
the same timeframe (last month), e.g. alcohol, 
tobacco.
Part 1 – Polydrug Use (in the last month, age 15+)
u Twenty three percent of all adults aged 
15+ in Ireland had not used any substance 
(legal or illegal) in the month prior to the 
survey.
u Alcohol and tobacco use is the most 
common combination of polydrug use 
reported among all adults (10.5%).
u Among all adults, illegal drug use is most 
commonly combined with alcohol and 
tobacco use (2.0% of the population). 
Males are more likely to report use of illegal 
drugs combined with alcohol and tobacco 
(3.2% of males vs. 0.8% of females). This 
combination is more common than illegal 
drug use alone, or any other combination 
including illegal drug use.
u Females (26.0%) are more likely than 
males (20.3%) not to have used any 
substance (legal or illegal) during the last 
month.
u The proportion of females using other legal 
drugs2 in the previous month is more than 
double that reported by males (5.4% vs. 
2.6%).
u Those aged over 65 are more likely to 
report no drug use, either legal or illegal 
(35.8%), than young adults aged 15-
34 (22.0%) or older adults aged 35-64 
(20.1%).
u Those aged over 65 years report higher 
prevalence of use of other legal drugs 
(4.3%) than older adults (4.1%) or 
younger adults (3.8%).
u Older adults (aged 35-64) are more likely 
than younger adults (aged 15-34) to report 
the use of alcohol and anti-depressants 
(1.4% vs. 0.2%).
u Among people who use alcohol, males are 
more likely than females to have smoked 
tobacco (33.5% vs. 26.2%) in the last 
month, or to have used cannabis (8.3% 
vs. 3.1%).
u Since 2010/11 the proportion of people 
who use tobacco and who also use alcohol 
has decreased significantly for males and 
females (from 83.1% to 76.7% in males 
and from 72.5% to 64.9% in females). 
The proportion of people who use tobacco 
and who also use cannabis has increased 
significantly (from 11.2% to 17.6% in 
males and 3.1% to 7.7%% in females), 
and among young adults, this proportion 
has increased by 9.1 percentage points to 
20.1%.
u The proportion of respondents who use 
sedatives or tranquillisers and also use 
anti-depressants has increased since the 
2010/11 survey (+6.8 percentage points). 
Similarly, the proportion of those using 
anti-depressants who also use sedatives 
or tranquillisers has increased by 4.6 
percentage points.
Part 2 – New Psychoactive Substances
u Last year prevalence of use of new 
psychoactive substances has decreased 
significantly since the 2010/11 survey to 
0.8% (from 3.5%).
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1 “Legal drugs” refers to alcohol, tobacco, sedatives or tranquillisers, anti-depressants and ‘other legal drugs’.
2 Due to small numbers methadone, other opiates3 and anabolic steroids are grouped as ‘other legal drugs’.
3 Codeine, DF 118 30 tablets, Feminax, Kapake, Migraleve, Nurofen Plus, Panadeine tablets, Paracodin, Paramol, Solpadeine, Solpadol, 
Syndol, Tylex, Unifu Plus with Vitamin C, Veganin Plus, Tramadol, Opiates (excluding heroin & methadone), Temgesic®, Kapake®, 
Morphine, Opium, DF118 ® (DF’s), Diffs, Dikes, Peach, Fentanyl (Durogesic ® & Sublimaze ® & Actiq ®), Oxycodone (Oxycontin 
® & Oxynorm ®), MST ® (MST’s), Buprenorphine (Subutex ®), Diconal ®, Pethidine, Napps.
u Among young adults 6.0% report ever 
taking new psychoactive substances in their 
lifetime, but just 0.1% report use in the 
month prior to the survey.
u Last year use of new psychoactive 
substances is highest in those who are 
unemployed (2.2%).
u Those renting from a private landlord 
are most likely to have ever taken new 
psychoactive substances in their lifetime 
(6.6%) or in the last year (1.8%). 
Respondents who own their dwelling either 
in part or full, are least likely to have ever 
taken new psychoactive substances in their 
lifetime (1.5%), or to have taken them in 
the last year (0.3%).
u Analysis of prevalence of new psychoactive 
substances by education level attained 
shows that those with more education 
are most likely to take new psychoactive 
substances in their lifetime with 3.3% of 
those with a third level education ever 
taking new psychoactive substances in their 
lifetime compared to 1.2% of those with no 
formal education/primary education.
u Last year use is highest for single/never 
married individuals and those who are co-
habiting (both 1.4%) and lowest in those 
who are widowed (0%).
Introduction
This bulletin presents findings regarding polydrug 
use and use of new psychoactive substances in 
Ireland from the fourth drug prevalence survey 
of households in Ireland and Northern Ireland. 
Within Ireland the survey sampled a representative 
number of people aged 15+ from August 2014 
to August 2015. Part 1 of the bulletin presents 
prevalence rates and other relevant information 
regarding current polydrug use; that is, the use of 
more than one substance within the last month. 
Part 2 of this bulletin presents results regarding 
use of new psychoactive substances on lifetime 
(ever used), last year prevalence (recent use) 
and last month (current use) prevalence rates for 
Ireland. The survey was carried out according to 
standards set by the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA).
The Drug Prevalence Survey 2014/15 for the 
Republic of Ireland introduced a number of 
key changes to the questionnaire and sample 
population targeted, most notably:
u The sample population was extended from 
15-64 years to include all those aged 15+ 
years.
u A new section focusing on gambling 
prevalence was included.
These changes, therefore, require some 
modification of the bulletin layout to ensure that 
the valuable insights garnered from the trend data 
of 15-64 year olds is continued, but also to ensure 
that the 2014/15 data of all those aged 15+ is 
adequately addressed.
The survey was commissioned by the National 
Advisory Committee on Drugs and Alcohol 
(NACDA) in Ireland and the Public Health 
Information & Research Branch (PHIRB) within 
the Department of Health, in Northern Ireland. 
The main focus of the survey was to obtain 
prevalence rates for key illegal drugs, such as 
cannabis, ecstasy, cocaine and heroin on a 
lifetime (ever used), last year (recent use), and 
last month (current use) basis. Similar prevalence 
questions were also asked of alcohol, tobacco, 
and other drugs (e.g. tranquillisers); attitudinal and 
demographic information was also sought from 
respondents.
Methodology
The questionnaire and methodology for this 
general population survey were based on best 
practice guidelines drawn up by the EMCDDA. 
The questionnaires were administered through 
face-to-face interviews with respondents aged 
15+ years in Ireland who are normally resident 
in households. Thus persons outside these age 
ranges, or who do not normally live in private 
households, have not been included in the survey 
(for example prisons, nursing homes etc.).
Fieldwork for the survey was carried out between 
August 2014 and August 2015 and the final 
achieved sample comprised of 7,005 respondents 
in the Republic of Ireland. The response rate for 
the survey was 61%.
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Area-based sampling was applied. A three-stage 
process was used to construct the sample for 
this survey. The first stage involved stratifying 
by former Health Board regions in Ireland and 
sampling within each Health Board was primarily in 
proportion to the population. The achieved sample 
was weighted by gender, age and former Health 
Board region to maximise its representativeness of 
the general population. Details of the methodology 
can be found in the technical report.
Interviews were conducted using computer-
assisted personal interviewing (CAPI). These 
techniques allow interviews to be conducted 
more efficiently and more accurately than other 
techniques, such as pen-and-paper completion.
Reliability of the Estimates
The tests of statistical significance are used to 
establish the degree of confidence with which 
we can infer that the observed changes in drug 
prevalence between 2014/15 and 2010/11 
are not due to sampling error. For the change 
in prevalence over time, a significance level of 
5% has been specified which means that the 
likelihood that sampling error accounts for the 
observed change is less than 5%. More stringent 
criteria are used for the tests of association; for 
instance between prevalence and socio-economic 
group, significance levels of 1% and 0.1% are 
used.
In statistical testing, a result is deemed statistically 
significant if it is unlikely to have occurred by 
chance, and hence provides enough evidence 
to reject the hypothesis of ‘no effect’. As used in 
statistics, significant does not mean important 
or meaningful. A small, but important, real-world 
difference may fail to reach significance in a 
statistical test. Conversely, a statistically significant 
finding may have no practical consequence. This is 
especially important to remember when working 
with large sample sizes because any difference 
can be statistically significant if the samples are 
extremely large. Whether the change is of practical 
importance is reflected in an evaluation of effect 
size, which is a substantive issue.
Limitations of the General 
Population Survey Methodology
A general population drug prevalence survey 
has some limitations. Some groups with high 
drug use prevalence are not covered by the 
general population survey method (for example 
the homeless, those in prison etc.). Additionally, 
drug prevalence questions are considered to be 
sensitive and therefore people may refuse to 
participate or they may under-report their drug 
use. Moreover, for some groups the numbers can 
be too small for reliable prevalence estimations 
and for these specific groups, general population 
prevalence estimates can be supplemented by 
other methods (e.g. capture-recapture for problem 
drug use and surveys targeting special populations 
(e.g. prisoners, students, early school leavers).)
What is prevalence?
The term prevalence refers to the proportion of a 
population who have used a drug over a particular 
time period. In general population surveys, 
prevalence is measured by asking respondents in a 
representative sample drawn from the population 
to recall their use of drugs. The three most widely 
used recall periods are: lifetime (ever used a drug), 
last year (used a drug in the last twelve months), 
and last month (used a drug in the last month). 
Provided that a sample is representative of the 
total population, prevalence information obtained 
from a sample can be used to infer prevalence in 
the population.
Lifetime prevalence refers to the proportion of the 
sample that reported ever having used the named 
drug at the time they were surveyed. A person 
who records lifetime prevalence may or may not 
be currently using the drug. Lifetime prevalence 
should not be interpreted as meaning that people 
have necessarily used a drug over a long period of 
time or that they will use the drug in future.
Last year prevalence refers to the proportion of 
the sample that reported using a named drug in 
the year prior to the survey. Last year prevalence is 
often referred to as recent use.
Last month prevalence refers to the proportion of 
the sample that reported using a named drug in 
the 30-day period prior to the survey. Last month 
prevalence is often referred to as current use. 
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A proportion of those reporting current use may 
only use occasionally (or for the first-time) and 
happen to have used in the period leading up to 
the survey. It should therefore be appreciated that 
current use is not synonymous with regular use.
Understanding the Results of this 
Bulletin
Part 1 of this bulletin contains prevalence rates 
and other relevant information regarding current 
polydrug use; that is, the use of any two or more 
substances, legal, illegal or prescribed, in the same 
timeframe (last month), e.g. alcohol, tobacco. 
Results are given for all respondents (all adults 
aged 15+ years) and for gender and age (15-34, 
35-64 and 65+ years) categories.
Due to changes in the combinations of polydrug 
use since the last survey, comparisons between 
2014/15 and earlier survey results are not 
presented for prevalence of use. Comparisons 
between 2014/15 and earlier survey results are 
presented for use of one substance by use of 
another substance.
Part two of this bulletin presents prevalence rates 
of the use of new psychoactive substances, on a 
lifetime (ever used), last year prevalence (recent 
use) and last month (current use) basis.
All prevalence rates presented in the 
accompanying tables are rounded to one decimal 
place. As in all sample surveys, the greater the 
sample size the more statistically reliable are the 
results. Some of the differences in prevalence rates 
in the tables will be attributable to natural sample 
variations. Percentages may not always sum to 
100 due to either the effect of rounding or that 
respondents could give more than one answer.
Those over 65 were included in the Republic 
of Ireland survey for the first time in 2014/15, 
therefore the current results report prevalence 
levels of all those aged 15+ years, while the 
comparative results are provided for those aged 
15-64 years.
For the purpose of this study:
u ‘Legal drugs’ refers to alcohol, tobacco, 
sedatives or tranquillisers, anti-depressants 
and ‘other legal drugs’. Due to small 
numbers methadone, other opiates4 and 
anabolic steroids are grouped as ‘other legal 
drugs’.
u ‘Any illegal drugs’ refers to cannabis, 
cocaine (including crack), ecstasy, cocaine 
powder, magic mushrooms, amphetamines, 
poppers, LSD, new psychoactive substances, 
solvents, crack, and heroin. Please note the 
addition of new psychoactive substances 
into this category for 2014/15 following the 
Criminal Justice (Psychoactive Substances) 
Act 2010 in the Republic of Ireland.
u ‘No legal or illegal drugs’ refers to the use of 
none of the above specified (legal or illegal) 
drugs in the last month.
Polydrug Use in Ireland
There are a number of forms of polydrug use. The 
definition reported in this bulletin is: the use of any 
two or more substances, legal, illegal or prescribed, 
in the same timeframe (last month).
Polydrug use is associated with a number of 
negative consequences including mental and 
physical ill-health, violence, aggression and a range 
of social problems. Polydrug use is more likely 
to result in accidents and death (including death 
from overdose) than when a single substance is 
consumed.
There is evidence that polydrug use is common 
among people seeking drug treatment. The 
majority of cases treated in 2010 in Ireland 
reported problem drug use of more than one 
substance (65%) (HRB 2011)5. Polydrug use is 
more complex to treat, requiring services that can 
treat both alcohol and other drug dependence 
while providing a broad range of interventions, 
and is associated with poorer treatment outcomes. 
Earlier research shows that the pattern of use 
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4 Codeine, DF 118 30 tablets, Feminax, Kapake, Migraleve, Nurofen Plus, Panadeine tablets, Paracodin, Paramol, Solpadeine, Solpadol, 
Syndol, Tylex, Unifu Plus with Vitamin C, Veganin Plus, Tramadol, Opiates (excluding heroin & methadone), Temgesic®, Kapake®, 
Morphine, Opium, DF118 ® (DF’s), Diffs, Dikes, Peach, Fentanyl (Durogesic ® & Sublimaze ® & Actiq ®), Oxycodone (Oxycontin 
® & Oxynorm ®), MST ® (MST’s), Buprenorphine (Subutex ®), Diconal ®, Pethidine, Napps.
5 Alcohol and Drug Research Unit of the Health Research Board (2011) Trends in treated problem drug use in Ireland, 2005 to 2010. 
Available at http://www.hrb.ie/publications.
of ‘additional’ substances was linked to the main 
problem substance, the most common additional 
problem substances were cannabis followed by 
cocaine and benzodiazepines.
In considering the results presented here, note 
that the figures for prevalence are for that specific 
combination of drugs ONLY. Thus, the figures for 
alcohol only refers to that group of people who 
consumed alcohol only, i.e. that group did not use 
any other substance during that specified interval. 
A higher percentage than this will actually have 
consumed alcohol, but will also have used another 
substance (for example, smoke tobacco). The 
important point is that the tables presented in this 
bulletin are not aimed at presenting information on 
the prevalence of individual substances, but rather 
at the prevalence of the combination of drugs.
Definition of New Psychoactive 
Substances
According to the Council of the European Union 
(Article 3 of Council Decision 2005/387/JHA 
of 10 May 2005 on the information exchange, 
risk assessment and control of new psychoactive 
substances), the term ‘new psychoactive 
substance’ refers to a new narcotic drug or a 
new psychotropic drug in pure form or in a 
preparation. Many of these substances mimic 
the most common illegal drugs cocaine, ecstasy, 
amphetamine and cannabis. The emergence 
of new psychoactive substances in Ireland was 
facilitated by the increase in the number of head 
shops and online retailers selling the substances 
and drug paraphernalia. The surge in availability 
of new psychoactive substances led to new 
legislation for drug control. The introduction of 
the Criminal Justice (Psychoactive Substances) 
Act 2010 made illegal, the sale, import, export 
or advertisement of unregulated psychoactive 
substances for human consumption. The Act also 
gave appropriate powers to An Garda Síochána 
and the Courts to intervene quickly to prevent 
trade in a non-criminal procedure; via the use 
of prohibition and closure orders.
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Results – Ireland
Part 1: Polydrug Use – Last Month
Table 1: Top 30 of last month prevalence of no drug, monodrug and polydrug use – All adults (15+) (%)
Substance Frequency 
n=7005 Percent
Alcohol 2289 32.7
No drug 1626 23.2
Alcohol and Tobacco 737 10.5
Alcohol and Other legal drugs 565 8.1
Tobacco 388 5.5
Other legal drugs 284 4.1
Alcohol, Tobacco and Other legal drugs 252 3.6
Alcohol, Tobacco and any illegal drugs 140 2.0
Tobacco and Other legal drugs 78 1.1
Alcohol and Anti-depressants 60 0.8
Sedatives or Tranquillisers 55 0.8
Anti-depressants 42 0.6
Alcohol and Sedatives 38 0.5
Alcohol, Tobacco, Other legal drugs and any illegal drugs 35 0.5
Alcohol, Tobacco and Anti-depressants 35 0.5
Alcohol and any illegal drugs 35 0.5
Alcohol, Other legal drugs and Sedatives or Tranquillisers 33 0.5
Tobacco and any illegal drugs 25 0.4
Alcohol, Tobacco and Sedatives 21 0.3
Alcohol, Tobacco, Other legal drugs and Anti-depressants 19 0.3
Other legal drugs, Anti-depressants and Sedatives or Tranquillisers 19 0.3
Anti-depressants and Sedatives or Tranquillisers 19 0.3
Tobacco and Anti-depressants 18 0.3
Other legal drugs and Sedatives or Tranquillisers 18 0.3
Other legal drugs and Anti-depressants 17 0.2
Tobacco and Sedatives or Tranquillisers 15 0.2
Alcohol, Tobacco, Anti-depressants and Sedatives or Tranquillisers 13 0.2
Alcohol, Anti-depressants and Sedatives or Tranquillisers 13 0.2
Tobacco, Other legal drugs and Anti-depressants 13 0.2
Tobacco, Anti-depressants and Sedatives or Tranquillisers 12 0.2
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
All adults – Table 1
Among adults aged 15+ years, 23.2% had not used any substance (either legal or illegal) in the last 
month.
The most commonly used substance is alcohol, with 32.7% reporting alcohol consumption in the 
month before the survey. The most common combination of substances in the population is alcohol 
and tobacco (10.5% report use of both in the last month), and the proportion of those reporting use 
of alcohol and other legal drugs is 8.1%.
The combination of alcohol, tobacco and any illegal drugs is 2.0%, higher than the proportion reporting 
use of tobacco and other legal drugs (1.1%), or alcohol and anti-depressants (0.8%).
All other combinations of polydrug use are reported by 0.5% of the population or lower.
Again it should be noted that prevalence rates are for the specific combination of substances ONLY 
and do not indicate the level of consumption of any individual substance on its own.
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Table 2: Top 30 of last month prevalence of no drug, monodrug and polydrug use – Males (15+) (%)
Substance Frequency 
n=3439
Percent
Alcohol 1266 36.8
No drug 698 20.3
Alcohol and Tobacco 454 13.2
Alcohol and Other legal drugs 237 6.9
Tobacco 185 5.4
Alcohol, Tobacco and Other legal drugs 112 3.3
Alcohol, Tobacco and any illegal drugs 110 3.2
Other legal drugs 90 2.6
Alcohol and any illegal drugs 31 0.9
Tobacco and any illegal drugs 20 0.6
Alcohol, Tobacco, Other legal drugs and any illegal drugs 18 0.5
Tobacco and Other legal drugs 18 0.5
Alcohol and Anti-depressants 17 0.5
Alcohol, Tobacco and Anti-depressants 16 0.5
Alcohol and Sedatives or Tranquillisers 15 0.4
Anti-depressants 14 0.4
Sedatives or Tranquillisers 12 0.4
Alcohol, Tobacco, Other legal drugs and Anti-depressants 11 0.3
Alcohol, Other legal drugs and Sedatives or Tranquillisers 11 0.3
Tobacco and Anti-depressants 8 0.2
Alcohol, Other legal drugs and any illegal drugs 7 0.2
Anti-depressants and Sedatives or Tranquillisers 7 0.2
Alcohol, Tobacco, Anti-depressants and Sedatives or Tranquillisers 6 0.2
Alcohol, Tobacco, Other legal drugs, any illegal drugs and Anti-
depressants
6 0.2
Tobacco, Anti-depressants and Sedatives or Tranquillisers 5 0.2
Tobacco and Sedatives or Tranquillisers 5 0.1
Other legal drugs, Anti-depressants and Sedatives or Tranquillisers 5 0.1
Alcohol, Tobacco and Sedatives or Tranquillisers 5 0.1
Alcohol, Other legal drugs, Anti-depressants and Sedatives or 
Tranquillisers
4 0.1
Alcohol, Anti-depressants and Sedatives or Tranquillisers 4 0.1
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 3: Top 30 of last month prevalence of no drug, monodrug and polydrug use – Females (15+) (%)
Substance Frequency 
n=3566
Percent
Alcohol 1022 28.7
No Drug 928 26.0
Alcohol and Other legal drugs 328 9.2
Alcohol and Tobacco 283 7.9
Tobacco 202 5.7
Other legal drugs 194 5.4
Alcohol, Tobacco and Other legal drugs 139 3.9
Tobacco and Other legal drugs 60 1.7
Alcohol and Anti-depressants 43 1.2
Sedatives or Tranquillisers 43 1.2
Alcohol, Tobacco and any illegal drugs 30 0.8
Anti-depressants 28 0.8
Alcohol and Sedatives or Tranquillisers 23 0.6
Alcohol, Other legal drugs and Sedatives or Tranquillisers 22 0.6
Alcohol, Tobacco and Anti-depressants 19 0.5
Alcohol, Tobacco, Other legal drugs and any illegal drugs 17 0.5
Other legal drugs and Anti-depressants 16 0.5
Alcohol, Tobacco and Sedatives or Tranquillisers 16 0.4
Other legal drugs and Sedatives or Tranquillisers 14 0.4
Other legal drugs, Anti-depressants and Sedatives or Tranquillisers 14 0.4
Anti-depressants and Sedatives or Tranquillisers 12 0.3
Tobacco and Anti-depressants 11 0.3
Tobacco, Other legal drugs and Anti-depressants 11 0.3
Tobacco and Sedatives or Tranquillisers 10 0.3
Tobacco, Other legal drugs, Anti-depressants and Sedatives or 
Tranquillisers
9 0.3
Alcohol, Anti-depressants and Sedatives or Tranquillisers 9 0.2
Alcohol, Tobacco, Other legal drugs and Anti-depressants 8 0.2
Alcohol, Other legal drugs and Anti-depressants 7 0.2
Alcohol, Tobacco, Anti-depressants and Sedatives or Tranquillisers 7 0.2
Alcohol, Other legal drugs, Anti-depressants and Sedatives or 
Tranquillisers
7 0.2
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
Gender – Tables 2 & 3
A higher percentage of females (26.0%) than males (20.3%) had not used any substance (legal or 
illegal) during the last month. A larger proportion of males consume alcohol (36.8%) compared to 
females (28.7%) and the same is true for the combination of alcohol and tobacco in the last month 
(13.2% of males vs. 7.9% of females). Females are more likely to report use of the combination of 
alcohol and other legal drugs compared to males (9.2% vs. 6.9%).
Males and females report similar proportions of tobacco only use in the previous month (5.4% males 
and 5.7% females). The proportion of females using other legal drugs in the previous month is more 
than double that reported by males (5.4% vs. 2.6%).
Males are more likely to report use of illegal drugs combined with alcohol and tobacco (3.2% of males 
vs. 0.8% of females).
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Table 4: Top 30 of last month prevalence of no drug, monodrug and polydrug use – 
Young Adults (15-34) (%)
Substance Frequency 
n=2592
Percent
Alcohol 743 28.7
No Drug 571 22.0
Alcohol and Tobacco 327 12.6
Alcohol and Other legal drugs 221 8.5
Alcohol, Tobacco and Other legal drugs 147 5.7
Tobacco 142 5.5
Alcohol, Tobacco and any illegal drugs 112 4.3
Other legal drugs 100 3.8
Tobacco and Other legal drugs 35 1.4
Alcohol and any illegal drugs 31 1.2
Alcohol, Tobacco, Other legal drugs and any illegal drugs 30 1.2
Tobacco and any illegal drugs 22 0.8
Anti-depressants 12 0.5
Alcohol, Tobacco, Other legal drugs and Anti-depressants 10 0.4
Alcohol, Other legal drugs and any illegal drugs 9 0.3
Alcohol, Tobacco and Anti-depressants 9 0.3
Tobacco, Anti-depressants and Sedatives or Tranquillisers 6 0.2
Other legal drugs and Anti-depressants 6 0.2
Tobacco, Other legal drugs, Anti-depressants and Sedatives 
or Tranquillisers
5 0.2
Alcohol, Tobacco, Other legal drugs, any illegal drugs and 
Anti-depressants
5 0.2
Alcohol and Anti-depressants 4 0.2
Tobacco, Other legal drugs and Anti-depressants 4 0.1
Alcohol, Other legal drugs and Anti-depressants 4 0.1
Alcohol, Tobacco and Sedatives or Tranquillisers 3 0.1
Alcohol, Other legal drugs and Sedatives or Tranquillisers 3 0.1
Alcohol and Sedatives or Tranquillisers 3 0.1
Alcohol, Tobacco, Other legal drugs, any illegal drugs, 
Anti-depressants and Sedatives or Tranquillisers
3 0.1
Sedatives or Tranquillisers 2 0.1
Any illegal drugs 2 0.1
Alcohol, Tobacco, Other legal drugs, any illegal drugs and Sedatives 
or Tranquillisers
2 0.1
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 5: Top 30 of last month prevalence of no drug, monodrug and polydrug use – 
Older Adults (35-64) (%)
Substance Frequency 
n=3345
Percent
Alcohol 1217 36.4
No drug 672 20.1
Alcohol and Tobacco 365 10.9
Alcohol and Other legal drugs 290 8.7
Tobacco 195 5.8
Other legal drugs 138 4.1
Alcohol, Tobacco and Other legal drugs 97 2.9
Alcohol and Anti-depressants 46 1.4
Tobacco and Other legal drugs 34 1.0
Alcohol, Tobacco and any illegal drugs 29 0.9
Alcohol, Tobacco and Anti-depressants 21 0.6
Alcohol, Other legal drugs and Sedatives or Tranquillisers 20 0.6
Sedatives or Tranquillisers 18 0.5
Anti-depressants 18 0.5
Tobacco and Anti-depressants 15 0.5
Other legal drugs, Anti-depressants and Sedatives or Tranquillisers 15 0.4
Alcohol and Sedatives or Tranquillisers 13 0.4
Alcohol, Tobacco and Sedatives or Tranquillisers 12 0.3
Alcohol, Tobacco, Anti-depressants and Sedatives or Tranquillisers 10 0.3
Anti-depressants and Sedatives or Tranquillisers 10 0.3
Other legal drugs and Anti-depressants 10 0.3
Alcohol, Tobacco, Other legal drugs and Anti-depressants 9 0.3
Tobacco, Other legal drugs and Anti-depressants 9 0.3
Alcohol, Anti-depressants and Sedatives or Tranquillisers 9 0.3
Alcohol, Other legal drugs, Anti-depressants and Sedatives 
or Tranquillisers
8 0.2
Alcohol, Other legal drugs and Anti-depressants 7 0.2
Tobacco and Sedatives or Tranquillisers 7 0.2
Alcohol, Tobacco, Other legal drugs and Sedatives or Tranquillisers 6 0.2
Tobacco, Other legal drugs, Anti-depressants and Sedatives 
or Tranquillisers
6 0.2
Other legal drugs and Sedatives or Tranquillisers 6 0.2
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 6: Prevalence of no drug, monodrug and polydrug use – Over 65s (%)
Substance Frequency 
n=1039
Percent
No drug 372 35.8
Alcohol 320 30.7
Alcohol and Other legal drugs 52 5.0
Tobacco 49 4.7
Alcohol and Tobacco 45 4.3
Other legal drugs 45 4.3
Sedatives or Tranquillisers 34 3.3
Alcohol and Sedatives or Tranquillisers 20 1.9
Anti-depressants 12 1.2
Other legal drugs and Sedatives or Tranquillisers 12 1.1
Alcohol, Other legal drugs and Sedatives or Tranquillisers 10 0.9
Tobacco and Other legal drugs 9 0.8
Alcohol and Anti-depressants 8 0.8
Anti-depressants and Sedatives or Tranquillisers 8 0.8
Tobacco and Sedatives or Tranquillisers 8 0.8
Alcohol, Tobacco and Other legal drugs 7 0.7
Alcohol, Tobacco and Sedatives or Tranquillisers 6 0.6
Alcohol, Tobacco and Anti-depressants 5 0.5
Alcohol, Anti-depressants and Sedatives or Tranquillisers 4 0.4
Tobacco, Anti-depressants and Sedatives or Tranquillisers 3 0.3
Other legal drugs, Anti-depressants and Sedatives or Tranquillisers 2 0.2
Alcohol, Tobacco, Anti-depressants and Sedatives or Tranquillisers 2 0.2
Alcohol, Other legal drugs, Anti-depressants and Sedatives 
or Tranquillisers
2 0.2
Other legal drugs and Anti-depressants 2 0.1
Alcohol, Tobacco, Other legal drugs and Sedatives or Tranquillisers 2 0.1
Tobacco, Other legal drugs and Sedatives or Tranquillisers 1 0.1
Tobacco and Anti-depressants 1 0.1
Alcohol, Other legal drugs and Anti-depressants 1 0.1
Tobacco, Other legal drugs, Anti-depressants and Sedatives 
or Tranquillisers
0.3 0.02
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
Age – Tables 4, 5 & 6
Similar percentages of young adults (15-34 years) and older adults (35-64 years) report no drug use 
during the month prior to the survey (22.0% and 20.1% respectively), while a larger proportion of over 
65s report no drug use for the last month (35.8%).
Prevalence of alcohol and tobacco use in young adults is 12.6%, higher than that reported by older 
adults (10.9%) and over 65s (4.3%). Polydrug use of alcohol and other legal drugs is similar for younger 
and older adults (8.5% and 8.7% respectively), and lower in over 65s (5.0%).
In younger adults illegal drugs are most commonly used in combination with alcohol and tobacco 
(4.3%), while 0.9% of older adults report this combination of polydrug use in the month before the 
survey. Older adults are more likely than younger adults to report the use of alcohol and anti-depressants 
(1.4% vs. 0.2%).
Those aged over 65 years report higher prevalence of use of other legal drugs (4.3%) than older adults 
(4.1%) or younger adults (3.8%).
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Table 7: Total proportion of people using one substance by proportion using another substance – 
Adults (15-64) (%)
Last month prevalence Use of Alcohol Use of Tobacco Use of Cannabis
06/07 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
4967 5126 5937 3653 3621 3856 1619 1451 1629 128 143 259
Alcohol 73.4 70.6 65.0 81.2 78.3† 71.5* 90.6 84.5 87.4
Tobacco 32.6 28.3 27.4 36.1 31.4† 30.2 88.3 76.7† 82.9
Cannabis 2.6 2.8 4.4 3.2 3.3 5.9* 7.0 7.6 13.2*
ATS1 0.4 0.1 1.0 0.5 0.1† 1.5* 1.0 0.3† 3.4* 11.7 2.2† 20.2*
Cocaine 0.5 0.5 0.5 0.7 0.7 0.8 1.2 1.4 1.5 11.7 7.4 8.9
ST2 3.0 2.8 3.3 2.6 2.6 2.7 4.1 4.5 4.6 5.5 9.0 4.6
AD3 3.1 4.1 4.8 2.6 3.7† 4.2 4.8 6.3 7.7 7.0 8.9 7.2
Use of ATS1 Use of Cocaine Use of ST2 Use of AD3
06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
19 5 60 25 26 30 147 142 193 154 209 285
Alcohol 100.0 100.0 97.1 100.0 100.0 100.0 65.3 65.2 54.8 62.1 63.5 56.3
Tobacco 84.2 88.3 90.9 80.0 77.2 83.6 45.6 46.1 38.6 50.0 43.5 44.1
Cannabis 78.9 62.4 87.4 60.0 40.9 76.6* 4.7 9.0 6.1 5.8 6.1 6.5
ATS1 25.0 14.1 50.1* 0.7 0.4 1.3 0.6 1.2 2.6
Cocaine 33.3 74.1 25.1* 0.7 2.1 1.0 0.0 1.5 1.9
ST2 5.3 11.7 4.0 4.0 11.4 6.7 38.3 26.2† 30.8
AD3 5.3 52.9† 12.1* 0.0 12.4 17.6 40.1 38.5 45.3
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/07 and 2010/11
* Denotes a statistically significant change (p<0.05) between 2010/11 and 2014/15
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
Relationship between use of particular substances and use of other substances – 
All adults (Table 7)
Patterns of association between pairs of substances are presented in Table 7 for all adults aged 15-
64. Reading the table by column, of the respondents in the 2014/15 survey who used alcohol in the 
previous month, 30.2% also used tobacco, while 5.9% used cannabis. A large proportion of people who 
use tobacco reported use of alcohol (71.5%), cannabis (13.2%) and anti-depressants (7.7%).
Those using cannabis in the month prior to the survey are also likely to report alcohol use (87.4%) and/
or tobacco use (82.9%), while 20.2% of people who use cannabis also report use of amphetamine-type 
stimulants.
The majority of people who use amphetamine-type stimulants such as ecstasy or amphetamines also 
use alcohol (97.1%), tobacco (90.9%) and cannabis (87.4%), while 25.1% used cocaine in the last 
month.
All respondents who used cocaine in the previous month prior to the survey also used alcohol, 
83.6% used tobacco, 76.6% used cannabis and half of people who use cocaine (50.1%) also used 
amphetamine-type stimulants.
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Since the 2010/11 survey there has been a significant increase in the proportion of people who drink 
alcohol, people who use tobacco and people who use cannabis who use amphetamine-type stimulants 
(+1.4, +3.1 and +18.0 percentage points respectively). The proportion of those who used alcohol, 
tobacco or cocaine in the last month who also report cannabis use has increased significantly since 
2010/11 (+2.6, +5.6 and +35.7 percentage points respectively).
The proportion of respondents who use sedatives or tranquillisers and also use anti-depressants has 
increased since the 2010/11 survey (+6.8 percentage points). Similarly, the proportion of those using 
anti-depressants who also use sedatives or tranquillisers has increased by 4.6 percentage points.
Table 8: Total proportion of people using one substance by proportion using another substance – 
Males (15-64) (%)
Last month prevalence Use of Alcohol Use of Tobacco Use of Cannabis
06/07 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
2513 2554 2957 1966 1946 2078 844 800 909 99 119 196
Alcohol 78.2 76.3 70.3 87.6 83.1a† 76.7*b 92.0 84.4 87.5
Tobacco 33.6 31.3 30.7 37.6 34.2a† 33.5b 89.9 75.1† 81.3
Cannabis 4.0 4.7 6.6 4.7 5.2a 8.3*b 10.5 11.2a 17.6*b
ATS1 0.5 0.2 1.2 0.7 0.2† 1.6* 1.4 0.5 3.4* 11.1 2.2† 14.7*
Cocaine 0.7 0.8 0.9 1.0 1.0 1.2 1.9 1.8 2.3 12.0 8.0 10.0
ST2 2.4 2.3 2.4 2.0 2.1 2.1 3.4 3.5 3.7 4.0 7.4 4.6
AD3 2.3 3.2 3.9 1.9 2.3a 3.6* 3.3 4.5a 7.1* 5.1 7.3 7.6
Use of ATS1 Use of Cocaine Use of ST2 Use of AD3
06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
13 4 34 19 19 26 60 58 70 58 80 114
Alcohol 100.0 100.0 96.8 100.0 100.0 100.0 63.9 70.6 63.0 63.8 55.7 66.5
Tobacco 92.3 100.0 88.7 84.2 75.6 80.7 47.5 49.2 48.0 48.3 44.8 56.6
Cannabis 84.6 67.0 83.9 63.2 49.7 76.7 6.6 15.3a 13.1 8.6 10.9 13.0
ATS1 26.3 13.5 43.4* 0.0 0.0 0.0 0.0 2.5 3.7
Cocaine 38.5 67.0 32.2 0.0 1.4 2.2 0.0 2.5 4.2
ST2 0.0 0.0 0.0 0.0 4.1 5.9 38.6 23.8 30.5
AD3 0.0 52.5† 12.2 0.0 10.5 18.7 36.7 33.2 49.7
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/07 and 2010/11
* Denotes a statistically significant change (p<0.05) between 2010/11 and 2014/15
a Denotes a statistically significant difference between genders in 2010/2011
b Denotes a statistically significant difference between genders in 2014/2015
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
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Table 9: Total proportion of people using one substance by proportion using another substance – 
Females (15-64) (%)
Last month prevalence Use of Alcohol Use of Tobacco Use of Cannabis
06/07 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
2454 2572 2980 1678 1673 1778 776 651 719 28 24 63
Alcohol 68.4 65.1 59.7 74.4 72.5a 64.9*b 85.7 85.1 88.1
Tobacco 31.6 25.3 24.1 34.4 28.2a† 26.2b 85.7 84.7 87.8
Cannabis 1.1 0.9 2.1 1.4 1.2a 3.1*b 3.1 3.1a 7.7*b
ATS1 0.2 0.0 0.9 0.4 0.1 1.4* 0.5 0.1 3.3* 10.7 2.1 37.4*
Cocaine 0.2 0.3 0.2 0.4 0.4 0.3 0.5 0.8 0.6 10.7 4.5 5.4
ST2 3.5 3.3 4.1 3.4 3.1 3.5 5.0 5.7 5.7 10.7 17.1 4.3
AD3 3.9 5.0 5.7 3.5 5.3a† 4.8 6.3 8.5a 8.5 10.7 17.0 5.9
Use of ATS1 Use of Cocaine Use of ST2 Use of AD3
06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
6 1 26 6 7 5 87 85 124 96 129 171
Alcohol 100.0 100.0 97.4 100.0 100.0 100.0 66.3 61.5 50.1 61.5 68.3 49.5*
Tobacco 80.0 45.8 93.8 80.0 81.8 100.0 44.8 44.0 33.2 51.0 42.8 35.7
Cannabis 60.0 45.8 92.1 50.0 15.8 75.7* 3.4 4.8a 2.2 3.2 3.1 2.2
ATS1 33.3 15.8 88.4* 1.1 0.7 2.0 1.0 0.4 1.8
Cocaine 33.3 100.0 15.5* 1.1 2.5 0.4 0.0 0.9 0.3
ST2 16.7 54.2 9.5 16.7 32.1 11.6 38.5 27.7 31.0
AD3 16.7 54.2 12.0 0.0 17.5 11.6 42.5 42.1 42.8
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/07 and 2010/11
* Denotes a statistically significant change (p<0.05) between 2010/11 and 2014/15
a Denotes a statistically significant difference between genders in 2010/2011
b Denotes a statistically significant difference between genders in 2014/2015
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
Relationship between use of particular substances and use of other substances – 
Gender (Tables 8 & 9)
Tables 8 and 9 present patterns of association between pairs of substances for males and females 
aged 15-64.
Among people who drink alcohol, males are more likely than females to have smoked tobacco (33.5% 
vs. 26.2%) in the last month, and/or to have used cannabis (8.3% vs. 3.1%). Of those who used 
cannabis in the month before the survey females are more likely to also report use of amphetamine-type 
stimulants (37.4% vs. 14.7%). The proportion of males who use cannabis who report use of cocaine 
was almost double that of females (10.0% vs. 5.4%).
Males who took sedatives or tranquillisers in the last month are more likely than females to report 
alcohol use (63.0% vs. 50.1%) and/or tobacco use (48.0% vs. 33.2%). Similarly, males who took 
anti-depressants in the last month are more likely to report alcohol use (66.5% in males, 49.5% in 
females) or tobacco use (56.6% in males vs. 35.7% in females).
Since 2010/11 the proportion of people who use tobacco who also use alcohol has decreased 
significantly for males and females (-6.4 percentage points in males vs. -7.6 in females), while the 
proportion of people who use tobacco who use cannabis has increased significantly (+6.4 percentage 
points in males vs. +4.6% in females).
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Table 10: Total proportion of people using one substance by proportion using another substance – 
Younger adults (15-34) (%)
Last month prevalence Use of Alcohol Use of Tobacco Use of Cannabis
06/07 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
2315 2254 2592 1709 1597 1675 883 706 851 97 102 210
Alcohol 73.8 70.9 64.6 84.8 82.4a 74.9* 93.8 86.4 87.3
Tobacco 36.0 31.3 32.8 41.3 36.4a† 38.1b 89.7 75.4† 81.7
Cannabis 4.2 4.5 8.1 5.3 5.5a 10.9*b 10.4 11.0a 20.1*b
ATS1 0.7 0.1 2.2 1.0 0.1† 3.2*b 1.7 0.2† 6.0*b 13.4 0.0† 23.9*
Cocaine 1.0 1.0 0.9 1.3 1.4a 1.3 2.2 2.3a 2.0 14.4 7.4 8.4
ST2 1.3 1.0 1.6 1.2 1.0a 1.2b 1.7 1.6a 3.0 1.0 3.1a 3.1
AD3 2.2 2.3 3.0 2.0 2.2a 2.4b 3.0 4.7a 5.4 4.1 4.7a 4.6
Use of ATS1 Use of Cocaine Use of ST2 Use of AD3
06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted 
N
17 2 56 23 22 22 30 24 40 50 51 79
Alcohol 100.0 100.0 96.8 100.0 100.0 100.0 70.0 69.7 51.4 68.0 68.5 51.1
Tobacco 82.4 68.9 91.2 78.3 73.2 77.7 48.3 48.0 62.5 50.0 64.3a 58.6
Cannabis 76.5 0.0† 89.4*b 58.3 34.2 79.9* 3.3 13.3 16.3 7.8 9.5 12.2
ATS1 21.7 2.6a 52.3* 3.3 2.4 4.7 2.0 1.1 5.6
Cocaine 31.3 31.1 20.7b 3.3 10.8a 2.3 0.0 2.3 2.3
ST2 5.9 31.1 3.4 4.2 11.5 4.1 24.0 13.1a 27.7
AD3 5.9 31.1 7.8b 0.0 5.3a 8.2 40.0 28.4 54.0
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/07 and 2010/11
* Denotes a statistically significant change (p<0.05) between 2010/11 and 2014/15
a Denotes a statistically significant difference between younger and older adults in 2010/2011
b Denotes a statistically significant difference between younger and older adults in 2014/2015
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
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Table 11: Total proportion of people using one substance by proportion using another substance – 
Older adults (35-64) (%)
Last month prevalence Use of Alcohol Use of Tobacco
06/07 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted N 2652 2872 3345 1935 2023 2182 787 745 777
Alcohol 73.0 70.4 65.2 77.5 74.5a 67.7*
Tobacco 29.7 25.9 23.2 31.5 27.4a† 24.1*b
Cannabis 1.2 1.4 1.5 1.3 1.6a 2.0b 3.3 4.3a 5.6b
ATS1 0.1 0.1 0.1 0.1 0.2 0.2b 0.3 0.4 0.4b
Cocaine 0.0 0.1 0.2 0.1 0.2a 0.4 0.1 0.5a 1.0
ST2 4.4 4.1 4.6 3.9 3.8a 3.9b 6.7 7.3a 6.4
AD3 3.9 5.5 6.2 3.2 4.8a† 5.5b 6.6 7.8a 10.2
Use of Cannabis Use of ATS1 Use of Cocaine
06/7 10/11 14/15 06/7 10/11 14/15 06/7 10/11 14/15
Total weighted N 31 41 49 2 3 4 1 4 8
Alcohol 80.6 79.7 88.8 100.0 100.0 100.0 100.0 100.0 100.0
Tobacco 83.9 79.8 88.1 100.0 100.0 86.5 100.0 100.0 100.0
Cannabis 100.0 100.0 59.2b 100.0 79.2 67.3
ATS1 6.5 7.6 4.8 100.0 79.2a 43.8
Cocaine 3.3 7.6 10.8 50.0 100.0 86.5b
ST2 19.4 24.0a 10.7 0.0 0.0 13.1 0.0 10.4 14.1
AD3 16.7 19.5a 18.2 0.0 66.0 72.3b 0.0 52.2a 44.1
Use of ST2 Use of AD3
06/7 10/11 14/15 06/7 10/11 14/15
Total weighted N 118 119 153 103 158 206
Alcohol 64.1 64.3 55.6 59.2 61.8 58.3
Tobacco 44.9 45.7 32.3* 50.0 36.8a† 38.6
Cannabis 5.1 8.2 3.5 4.9 5.0 4.4
ATS1 0.0 0.0 0.3 0.0 1.3 1.4
Cocaine 0.0 0.3a 0.7 0.0 1.3 1.7
ST2 45.6 30.5a† 32.0
AD3 39.8 40.5 43.0
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/07 and 2010/11
* Denotes a statistically significant change (p<0.05) between 2010/11 and 2014/15
a Denotes a statistically significant difference between younger and older adults in 2010/2011
b Denotes a statistically significant difference between younger and older adults in 2014/2015
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
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Relationship between use of particular substances and use of other substances – 
Age (Tables 10 & 11)
Tables 10 and 11 present patterns of association between pairs of substances for younger and older 
adults. For people who drink alcohol, young adults are more likely to also report use of tobacco (38.1% 
vs. 24.1% in older adults). Young adults who consume alcohol are also more likely to report cannabis use 
(10.9% vs. 2.0% in older adults) and/or amphetamine-type stimulants (3.2% vs. 0.2% in older adults).
Of those who used tobacco in the last month prior to the survey, young adults are more likely to also 
report alcohol use (74.9% vs. 67.7% of older adults), cannabis use (20.1% vs. 5.6% of older adults) 
and/or amphetamine-type stimulants (6.0% vs. 0.4% in older adults).
Among people who use cannabis, older adults are more likely to also take cocaine (10.8% vs. 8.4% in 
younger adults), sedatives or tranquillisers (10.7% vs. 3.1% in younger adults), and/or anti-depressants 
(18.2% vs. 4.6% in younger adults). Younger adults who take cannabis are more likely than older adults 
to also take amphetamine-type stimulants (23.9% vs. 4.8%).
Since the 2010/11 survey, the proportion of young adults who use cannabis who also took 
amphetamine-type stimulants in the last month has increased significantly by 23.9 percentage points 
from 0%. The proportion of young adults who use tobacco and also report cannabis use has increased 
by 9.1 percentage points to 20.1%.
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Part 2: New Psychoactive Substances
Table 12: Prevalence of use of new psychoactive substances in Ireland 2010/11 and 2014/15 – 
Adults (15+) (%)
All adults
(15-64)
Male (15-64) Female (15-64) Young Adults 
(15-34)
Older Adults 
(35-64)
65+
10/11 14/15 10/11 14/15 10/11 14/15 10/11 14/15 10/11 14/15 14/15
Total Weighted N 
(valid responses)
5127 5937 2553 2957 2574 2980 2254 2592 2873 3345 1039
Lifetime prevalence 
(ever used)
- 3.5 - 4.7 - 2.3 - 6.0 - 1.5 0.3
Last year prevalence 
(recent use)
3.5 0.8* 5.4 1.2* 1.6 0.5* 6.7 1.6* 1.0 0.2* 0.0
Last month prevalence 
(current use)
- 0.1 - 0.1 - 0.1 - 0.1 - 0.0 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Denotes a statistically significant change (p<0.05) between 2010/11 and 2014/15
Last year prevalence of use of new psychoactive substances has decreased significantly since the 
2010/11 survey to 0.8% (from 3.5%). Males, females, young and older adults have seen significant 
decreases in last year use of new psychoactive substances. This follows the introduction of the Criminal 
Justice (Psychoactive Substances) Act 2010.
Among young adults 6.0% report ever taking new psychoactive substances in their lifetime, but just 0.1% 
report use in the month prior to the survey. Last year use is higher among males (1.2%) than females 
(0.5%).
Table 13: Age at first use of new psychoactive substances (People who have used in their lifetime, 15+) 
(%)
Adults 
(15+)
Males Females Young 
adults 
(15-34)
Older 
adults 
(35-64)
65+
Total weighted N (valid responses) 205 137 68 153 51 2
Median age 20 22 19 19 28 56
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
Among adults over 15 years old, the median age at first use of new psychoactive substances is 20. 
Median age at first use is higher in males than females (22 vs. 19) and lower in young adults than older 
adults (19 vs. 28).
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Profile of people who have used new psychoactive substances
New Psychoactive Substances prevalence by Socio-economic Group (SOC2000 Classification)4
Table 14: Prevalence of new psychoactive substances by socio-economic group (SOC2000 
Classification) – Adults 15+ (%)
Lifetime
(Ever used)
Last year
(Recent use)
Last month
(Current use)
A: Professional, senior management, top civil servants n=192) 0.8 0.0 0.0
B: Middle management, senior civil servants, managers and 
owners of own business (n=1046)
2.9 0.8 0.0
C1: Junior management and owners of small business 
(n= 1913)
3.4 0.9 0.1
C2: Skilled manual workers and manual workers responsible 
for other workers (n=1304)
3.1 0.7 0.0
D: Semi-Skilled and unskilled manual workers, trainees 
and apprentices (n=925)
2.4 0.3 0.0
E: All those dependent on the state long term (n=1266) 3.4 0.8 0.1
F1: Farmer 50+ acres (n=254) 0.8 0.2 0.0
F2: Farmer <50 acres (n=104) 3.4 0.3 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Analysis of prevalence of new psychoactive substances by socio-economic group status shows that 
lifetime rates are highest in Groups C1 (Junior management and owners of small business), E (All those 
dependent on the state long term) and F2 (Farmer <50 acres), all with 3.4%.
Last year use of new psychoactive substances is highest in group C1 (Junior management and owners of 
small business) with 0.9% reporting use, and lowest in group A (Professional, senior management, top 
civil servants) with 0% reporting use in the last month.
New Psychoactive Substances prevalence by Work Status
Table 15: Prevalence of new psychoactive substances by work status – Adults 15+ (%)
Lifetime
(Ever used)*
Last year
(Recent use)
Last month
(Current use)
At work (n=3600) 3.3 0.7 0.0
Unemployed (n=646) 7.6 2.2 0.2
Student (n=802) 2.9 0.9 0.2
Engage in home duties (n=852) 0.8 0.0 0.0
Retired (n=853) 0.2 0.1 0.0
Other (n=251) 3.6 1.4 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Analysis of prevalence of new psychoactive substances by work status shows that those who are 
unemployed are most likely to have ever taken new psychoactive substances in their lifetime (7.6%), 
while those who are retired report the lowest use (0.2%).
Last year use is also highest in the unemployed (2.2%) and lowest in those who are retired (0.1%) 
or engaged in home duties (0%).
Last month use is 0% in most groups except for the unemployed and students (both 0.2%).
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4 Official/international system for classifying socio-economic group.
New Psychoactive Substances prevalence by Housing tenure
Table 16: Prevalence of new psychoactive substances by housing tenure – Adults 15+ (%)
Lifetime
(Ever used)*
Last year
(Recent use)
Last month
(Current use)
Owned in part or full (n=4357) 1.5 0.3 0.0
Rented from private landlord (n=1221) 6.6 1.8 0.0
Rented from LA/HA (n=479) 3.5 0.9 0.1
Other (n=65) 5.6 1.5 0.0
Live with parents/other family (n=883) 5.0 1.0 0.3
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Analysis of prevalence of new psychoactive substances by housing tenure shows that those renting 
from a private landlord are most likely to take new psychoactive substances in their lifetime (6.6%) or 
in the last year (1.8%). Respondents who own their dwelling either in part or full, are least likely to have 
ever taken new psychoactive substances in their lifetime (1.5%), or to have taken them in the last year 
(0.3%).
New Psychoactive Substances prevalence by Age Ceased Education
Table 17: Prevalence of new psychoactive substances by age education ceased – Adults 15+ (%)
Lifetime
(Ever used)
Last year
(Recent use)
Last month
(Current use)
15 years and under (n=755) 2.6 0.5 0.0
16-19 years (n=2361) 2.4 0.4 0.1
20 years and over (n=2482) 3.4 0.8 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Lifetime prevalence of new psychoactive substances is highest among those who ceased education at 
20 years or over (3.4%). Last year use is also highest in this group (0.8%). Prevalence rates for those 
who ceased education at 15 years and under, and 16-19 years are similar for lifetime (2.6% vs. 2.4%) 
and last year use (0.5% vs. 0.4%).
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New Psychoactive Substances prevalence by Highest Education Level Attained
Table 18: Prevalence of new psychoactive substances by highest education level attained – 
Adults 15+ (%)
Lifetime
(Ever used)
Last year
(Recent use)
Last month
(Current use)
No formal education/primary (n=504) 1.2 0.0 0.0
Lower secondary (n=1376) 2.6 0.5 0.1
Upper Secondary (n=2012) 3.2 1.0 0.0
Third level (n=3088) 3.3 0.7 0.1
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Analysis of prevalence of new psychoactive substances by education level attained shows that those with 
more education are most likely to take new psychoactive substances in their lifetime with 3.3% of those 
with a third level education ever taking new psychoactive substances in their lifetime compared to 1.2% 
of those with no formal education/primary education.
Those with an upper secondary education report the highest last year use of new psychoactive 
substances (1.0%), followed by those with third level education (0.7%).
New Psychoactive Substances prevalence by Marital Status
Table 19: Prevalence of new psychoactive substances by highest marital status – Adults 15+ (%)
Lifetime
(Ever used)*
Last year
(Recent use)
Last month
(Current use)
Single/never married (n=2231) 5.0 1.4 0.2
Married (n=3531) 1.2 0.3 0.0
Co habiting (n=610) 8.1 1.4 0.0
Separated (n=187) 0.7 0.4 0.0
Divorced (n=115) 3.1 0.3 0.0
Widowed (n=315) 0.6 0.0 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses
* Wald-F statistical significance test (p <0.001) for a test of equality among groups.
Analysis of prevalence of new psychoactive substances by marital status shows that those who are 
co-habiting are most likely to take new psychoactive substances (8.1%) in their lifetime, while those 
who are widowed (0.6%) or separated (0.7%) report the lowest lifetime prevalence.
Last year use is highest for single/never married individuals and those who are co-habiting (both 1.4%) 
and lowest in those who are widowed (0%).
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